IS7315A - Útskipt díketópíperasín sem oxýtósínmótlyf - Google Patents

Útskipt díketópíperasín sem oxýtósínmótlyf

Info

Publication number
IS7315A
IS7315A IS7315A IS7315A IS7315A IS 7315 A IS7315 A IS 7315A IS 7315 A IS7315 A IS 7315A IS 7315 A IS7315 A IS 7315A IS 7315 A IS7315 A IS 7315A
Authority
IS
Iceland
Prior art keywords
diketopiperazine
replaced
oxytocin antagonist
oxytocin
antagonist
Prior art date
Application number
IS7315A
Other languages
English (en)
Other versions
IS2613B (is
Inventor
David Borthwick Alan
Jonathan Hatley Richard
Mary Bernadette Hickey Deirdre
Liddle John
George Hubert Livermore David
Mcmurtrie Mason Andrew
Derek Miller Neil
Nerozzi Fabrizio
Leslie Sollis Steven
Katrin Szardenings Anna
Graham Wyatt Paul
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of IS7315A publication Critical patent/IS7315A/is
Publication of IS2613B publication Critical patent/IS2613B/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS7315A 2001-12-21 2004-06-16 Útskipt díketópíperasín sem oxýtósínblokkar IS2613B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0130677.8A GB0130677D0 (en) 2001-12-21 2001-12-21 Medicaments and novel compounds
PCT/EP2002/014823 WO2003053443A1 (en) 2001-12-21 2002-12-20 Substituted diketopiperazines as oxytocin antagonists

Publications (2)

Publication Number Publication Date
IS7315A true IS7315A (is) 2004-06-16
IS2613B IS2613B (is) 2010-04-15

Family

ID=9928187

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7315A IS2613B (is) 2001-12-21 2004-06-16 Útskipt díketópíperasín sem oxýtósínblokkar

Country Status (28)

Country Link
US (3) US7514437B2 (is)
EP (1) EP1458393B1 (is)
JP (1) JP4638149B2 (is)
KR (2) KR20100060012A (is)
CN (1) CN100374115C (is)
AT (1) ATE399011T1 (is)
AU (1) AU2002364304B2 (is)
BR (1) BRPI0215277B1 (is)
CA (1) CA2471355C (is)
CO (1) CO5590916A2 (is)
CY (1) CY1108334T1 (is)
DE (1) DE60227283D1 (is)
DK (1) DK1458393T3 (is)
ES (1) ES2307827T3 (is)
GB (1) GB0130677D0 (is)
HK (1) HK1069339A1 (is)
HU (1) HU229708B1 (is)
IL (2) IL162515A0 (is)
IS (1) IS2613B (is)
MX (1) MXPA04006033A (is)
NO (1) NO329543B1 (is)
NZ (1) NZ533218A (is)
PL (1) PL215826B1 (is)
PT (1) PT1458393E (is)
RU (1) RU2303032C2 (is)
SI (1) SI1458393T1 (is)
WO (1) WO2003053443A1 (is)
ZA (1) ZA200404326B (is)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0314738D0 (en) * 2003-06-24 2003-07-30 Glaxo Group Ltd Novel compounds
GB0314733D0 (en) * 2003-06-24 2003-07-30 Glaxo Group Ltd Medicaments
GB0414093D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414092D0 (en) * 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414100D0 (en) * 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0428235D0 (en) * 2004-12-23 2005-01-26 Glaxo Group Ltd Novel compounds
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
EP2280601A4 (en) * 2008-02-21 2012-08-29 Sequoia Pharmaceuticals Inc AMINO ACID HEMMER OF CYTOCHROM P450
BRPI0917818A2 (pt) * 2008-08-22 2017-02-21 British Columbia Cancer Agency Branch composto, método para modular a atividade de ar, uso de composto, composição farmacêutica, e, para preparar um composto
WO2011051814A1 (en) 2009-10-30 2011-05-05 Glaxo Group Limited Novel crystalline forms of (3r,6r) -3- (2, 3 -dihydro- 1h- inden- 2 -yl) - 1 - [ (1r) - 1 - (2, 6 - dimethyl - 3 - pyridinyl) - 2 - (4 -morpholinyl) -2-oxoethyl] -6- [(1s) - 1 -methylpropyl] -2,5- piperazinedione
SG190066A1 (en) * 2010-10-29 2013-06-28 Lonza Ag Diketopiperazine forming dipeptidyl linker
CN103242246A (zh) * 2013-05-21 2013-08-14 苏州科捷生物医药有限公司 3-位取代的n-甲基哌嗪的合成方法
CN105061317B (zh) * 2015-08-26 2017-08-25 浙江大果生物医药科技有限公司 一类吲唑盐类化合物及其制备方法和应用
LT3397622T (lt) 2016-01-04 2022-06-27 ObsEva S.A. Hidroksipropiltiazolidino karboksamido darinio alfa-amino esterio ir tokolitinio agento įvedimas kartu
WO2018015497A2 (en) 2016-07-21 2018-01-25 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
CN109305969B (zh) * 2017-07-27 2023-03-10 江苏恒瑞医药股份有限公司 哌嗪-2,5-二酮类衍生物、其制备方法及其在医药上的应用
CN109485598A (zh) * 2018-11-29 2019-03-19 河南师范大学 一种去除氨基上喹啉保护基的新方法
CN114667141A (zh) 2019-09-03 2022-06-24 奥布赛瓦股份公司 用于促进胚胎移植和预防流产的催产素拮抗剂给药方案
US20230102503A1 (en) 2020-02-10 2023-03-30 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596819A (en) * 1984-01-23 1986-06-24 Warner-Lambert Company Modified tripeptides
CZ56194A3 (en) * 1991-09-13 1995-06-14 Merck & Co Inc Derivatives of piperazinyl(sulfonyl) amide of camphor as oxytocin antagonists
US5464788A (en) * 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5817751A (en) 1994-06-23 1998-10-06 Affymax Technologies N.V. Method for synthesis of diketopiperazine and diketomorpholine derivatives
GB2326639A (en) * 1997-06-18 1998-12-30 Merck & Co Inc Piperazine Oxytocin Receptor Antagonists
GB9713748D0 (en) * 1997-06-27 1997-09-03 Unilever Plc Production of detergent granulates
IL137517A0 (en) 1998-01-27 2001-07-24 Aventis Pharm Prod Inc Substituted oxoazaheterocyclyl factor xa inhibitors
WO1999038844A1 (en) 1998-01-29 1999-08-05 Aventis Pharmaceuticals Products Inc. Method for preparing an n-[(aliphatic or aromatic)carbonyl]-2-aminoacetamide compound and a cyclyzed compound
US6107274A (en) * 1998-03-16 2000-08-22 Ontogen Corporation Piperazines as inhibitors of fructose-1,6-bisphosphatase (FBPase)
GB0314738D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Novel compounds
GB0314733D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Medicaments
GB0414093D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414092D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414100D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0428235D0 (en) 2004-12-23 2005-01-26 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
IL162515A0 (en) 2005-11-20
ATE399011T1 (de) 2008-07-15
CA2471355A1 (en) 2003-07-03
EP1458393B1 (en) 2008-06-25
HU229708B1 (en) 2014-05-28
PT1458393E (pt) 2008-09-29
KR20100060012A (ko) 2010-06-04
IL162515A (en) 2012-08-30
HUP0500136A2 (hu) 2005-05-30
PL215826B1 (pl) 2014-01-31
DE60227283D1 (de) 2008-08-07
HK1069339A1 (en) 2005-05-20
ZA200404326B (en) 2005-09-28
CN1606443A (zh) 2005-04-13
WO2003053443A1 (en) 2003-07-03
MXPA04006033A (es) 2004-09-27
US7514437B2 (en) 2009-04-07
NO329543B1 (no) 2010-11-08
US20050148572A1 (en) 2005-07-07
AU2002364304A1 (en) 2003-07-09
NO20043115L (no) 2004-07-20
CN100374115C (zh) 2008-03-12
RU2303032C2 (ru) 2007-07-20
KR20040065285A (ko) 2004-07-21
KR100997856B1 (ko) 2010-12-01
US20090186867A1 (en) 2009-07-23
JP2005517663A (ja) 2005-06-16
CA2471355C (en) 2013-04-23
BR0215277A (pt) 2004-12-14
CO5590916A2 (es) 2005-12-30
GB0130677D0 (en) 2002-02-06
CY1108334T1 (el) 2014-02-12
DK1458393T3 (da) 2008-10-13
BRPI0215277B1 (pt) 2016-05-03
US8541579B2 (en) 2013-09-24
US8367673B2 (en) 2013-02-05
IS2613B (is) 2010-04-15
ES2307827T3 (es) 2008-12-01
PL370981A1 (en) 2005-06-13
SI1458393T1 (sl) 2008-10-31
AU2002364304B2 (en) 2008-04-17
RU2004122392A (ru) 2005-04-20
US20130131338A1 (en) 2013-05-23
JP4638149B2 (ja) 2011-02-23
NZ533218A (en) 2007-01-26
EP1458393A1 (en) 2004-09-22

Similar Documents

Publication Publication Date Title
HK1069339A1 (en) Substituted diketopiperazines as oxytocin antagonists
CY1107853T1 (el) Χρησεις αντισπασμωδικων αμινοξεων για τη θεραπευτικη αγωγη διπολικων διαταραχων
CY1109242T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για θεραπεια πονου
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
IS8502A (is) Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
EP1248612A4 (en) NEW SUBSTANCES AND COMPOUNDS AS PROTEASE INHIBITORS
EA200300776A1 (ru) Производные фенэтаноламина для лечения респираторных заболеваний
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
IS8503A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
MXPA05003302A (es) Compuestos de piperazina terapeuticos.
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
RS20060280A (en) Novel keto-oxadiazole derivatives as cathepsin inhibitors
EA200301203A1 (ru) Новые соединения и композиции как ингибиторы катепсина
SE9902267D0 (sv) New compounds
WO2005035500A3 (en) Therapeutic agents useful for treating pain
YU59102A (sh) JEDINJENJA KORISNA ZA LEČENJE ILI PREVENCIJU OBOLJENJA U KOJEM UČESTVUJE ALFA-2β-ADRENOCEPTOR
ATE288254T1 (de) Methode zur behandlung von schlaganfall
DK1553938T3 (da) Anvendelse af epothilonderivater til behandling af hyperparathyroidisme
PT1370526E (pt) Diamidas que inibem a actividade da triptase e do factor xa
SG143979A1 (en) Novel compounds and compositions as cathepsin inhibitors